Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?

Steven A John, Thomas H F Whitfield, H Jonathon Rendina, Jeffrey T Parsons, Christian Grov, Steven A John, Thomas H F Whitfield, H Jonathon Rendina, Jeffrey T Parsons, Christian Grov

Abstract

Oral pre-exposure prophylaxis (PrEP) is highly effective at reducing HIV transmission risk and is CDC recommended for many gay, bisexual, and other men who have sex with men (GBM). We sought to investigate awareness of and preference for using long-acting injectable PrEP (LAI-PrEP) among GBM currently taking oral PrEP (n = 104), and identify their concerns. About half of GBM had heard of LAI-PrEP, and 30.8% specifically preferred LAI-PrEP. GBM with more concerns about the level of protection and drug half-life of LAI-PrEP had lower odds of preferring LAI-PrEP. Given that daily pill adherence is a challenge for some on PrEP, it is important to investigate the degree to which those on PrEP might consider LAI-PrEP as an alternative.

Keywords: HIV; Long-acting injectable; Men who have sex with men; Pre-exposure prophylaxis.

Conflict of interest statement

Disclosure of Potential Conflicts of Interest:

Conflict of Interest: The authors declare that they have no conflict of interest.

References

    1. CDC. HIV surveillance report, 2015. 2016;27 Available at: .
    1. USFDA. FDA approves first medication to reduce HIV risk. 2012 Available at: .
    1. CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States 2014. A clinical practice guideline. 2014 Available at: .
    1. Lieb S, Thompson DR, Misra S, et al. Estimating populations of men who have sex with men in the southern United States. J Urban Health. 2009;86(6):887–901.
    1. Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States: The Motivational PrEP Cascade. J Acq Immun Def Synd. 2017;74(3):285–292.
    1. Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013–2015). 21st International AIDS Conference; Durban, Africa. 2016.
    1. Buchbinder S, Liu A. CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention. Top Antiviral Med. 2016;24(1):10–28.
    1. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: Facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.
    1. Roberts ST, Heffron R, Ngure K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav. 2014;18(9):1701–11.
    1. Greene GJ, Swann G, Fought AJ, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2016;21(5):1336–1349.
    1. Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the US. AIDS Behav. 2016;20(7):1390–9.
    1. Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: A P18 cohort substudy. PLoS One. 2014;9(12):e114700.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren